| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697003 | Brachytherapy | 2017 | 8 Pages |
Abstract
In intermediate-risk prostate cancer, combo-RT improved bRFS but not DMFS and increased Grade 3 GU toxicity. The bRFS benefit was limited to unfavorable intermediate-risk patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ahmed E. Abugharib, Robert T. Dess, Payal D. Soni, Vrinda Narayana, Cheryl Evans, Mohamed S. Gaber, Felix Y. Feng, Patrick W. McLaughlin, Daniel E. Spratt,